Drug Search Results
More Filters [+]

Birabresib

Alternative Names: birabresib, otx015, mk-8628
Latest Update: 2024-04-25
Latest Update Note: PubMed Publication

Product Description

Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29733771/)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Birabresib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia|Glioblastoma

Phase 1: Non-Small-Cell Lung Cancer|NUT Carcinoma|Prostate Cancer|Triple Negative Breast Cancer|Ductal Breast Carcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Adenocarcinoma|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Diffuse Large B-Cell Lymphoma|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-8628-005

P1

Terminated

Acute Myeloid Leukemia|Myelodysplastic Syndrome|Diffuse Large B-Cell Lymphoma

2018-01-18

MK-8628-006

P1

Terminated

Triple Negative Breast Cancer|NUT Carcinoma|Prostate Cancer|Non-Small-Cell Lung Cancer

2017-04-26

MK-8628 Solid Tumor Trial

P1

Completed

NUT Carcinoma|Prostate Cancer|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer

2017-04-26

MK-8628-003

P1

Completed

Ductal Breast Carcinoma|NUT Carcinoma|Prostate Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma

2017-03-03

Recent News Events